Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393978 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
A Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00393978: Completed Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder, sponsored by University of Cincinnati.
NCT00393978 is a Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder that has completed, run by University of Cincinnati. The registered enrollment target is 75 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393978, a Phase 4 study of Bipolar Disorder and Cannabis-Related Disorder, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
Primary Outcome
Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.
Conditions Studied
Interventions
- DRUG Quetiapine and placebo
- DRUG Quetiapine and Topiramate
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
What the finished NCT00393978 record still lists
NCT00393978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Quetiapine and placebo is the first listed.
NCT00393978 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00393978 about?
NCT00393978 is a clinical study titled "Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania". The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
What is the current status of trial NCT00393978?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2006-11. Estimated completion is 2014-03.
What conditions does trial NCT00393978 study?
This clinical trial studies the following conditions: Bipolar Disorder, Cannabis-Related Disorder.
What interventions are being tested in trial NCT00393978?
The interventions under investigation include: Quetiapine and placebo (DRUG), Quetiapine and Topiramate (DRUG).
Who is sponsoring clinical trial NCT00393978?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393978 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00393978's enrollment target sits among peer trials
75 80th of 162 higher than 81 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia